Major Hepatic Resection for Hilar Cholangiocarcinoma: Analysis of 46 Patients

HYPOTHESIS Major hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma are associated with actual long-term (>5 years) survival. DESIGN Retrospective outcome study. SETTING Single tertiary referral institution. PATIENTS Between 1979 and 1997, 46 consecutive p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of surgery (Chicago. 1960) 2004-05, Vol.139 (5), p.514-525
Hauptverfasser: Rea, David J, Munoz-Juarez, Manuel, Farnell, Michael B, Donohue, John H, Que, Florencia G, Crownhart, Brian, Larson, Dirk, Nagorney, David M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 525
container_issue 5
container_start_page 514
container_title Archives of surgery (Chicago. 1960)
container_volume 139
creator Rea, David J
Munoz-Juarez, Manuel
Farnell, Michael B
Donohue, John H
Que, Florencia G
Crownhart, Brian
Larson, Dirk
Nagorney, David M
description HYPOTHESIS Major hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma are associated with actual long-term (>5 years) survival. DESIGN Retrospective outcome study. SETTING Single tertiary referral institution. PATIENTS Between 1979 and 1997, 46 consecutive patients had resection of hilar cholangiocarcinoma by major hepatectomy, bile duct resection, and regional lymphadenectomy. MAIN OUTCOME MEASURES Overall survival and tumor recurrence were correlated to clinicopathological factors, operative morbidity, and mortality. RESULTS Twenty-five patients underwent left hepatectomy, 17 underwent right hepatectomy, and 4 had extended right hepatectomy. Eighteen patients underwent resection of segment 1. Negative (R0) resection margins were achieved in 37 patients (80%). The operative mortality rate was 9%, and the surgical morbidity rate was 52%. Actual 1-year, 3-year, and 5-year survival rates were 80%, 39%, and 26%, respectively. Factors adversely associated with patient survival rates included: male sex, lymph node metastases, tumor grade 3 or 4, elevated direct serum bilirubin level at diagnosis, elevated preoperative activated partial thromboplastin time, and more than 4 U of red blood cells transfused perioperatively. Tumor size and R0 resection approached significance for survival. Factors associated with tumor recurrence included: male sex, tumor grade 3 or 4, a low hemoglobin level both at diagnosis and preoperatively, and a low preoperative prothrombin time and low alkaline phosphatase level at diagnosis and preoperatively. Median time to recurrence was 3.6 years. Tumor recurrence was predominantly local and regional. CONCLUSIONS The actual 5-year survival rate of 26% justifies major partial hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma. The high frequency of local and regional recurrence warrants investigation of adjuvant therapy.Arch Surg. 2004;139:514-525-->
doi_str_mv 10.1001/archsurg.139.5.514
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71911830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>396768</ama_id><sourcerecordid>638023181</sourcerecordid><originalsourceid>FETCH-LOGICAL-a295t-d832049d7f41050d4eb6f191cdd30b6ef84ac84c3e62cb3c88aa77c6b84df3483</originalsourceid><addsrcrecordid>eNpdkE1PxCAURYnR6PjxA3RhGhfuWoEHlLqbTPxKZqIxuiaU0plO2jJCu_Dfi5lRE1cQOPe-l4PQBcEZwZjcaG9WYfTLjECR8YwTtocmhINMQTC2jyYYY5ZGEh-h4xDW8UZlQQ_REeEEBHA6QYuFXjufPNqNHhqTvNpgzdC4Pqm_X5tW-2S2cq3ul40zcWDTu07fJtNet5-hCYmrEyaSlxi2_RBO0UGt22DPducJer-_e5s9pvPnh6fZdJ5qWvAhrSRQzIoqrxnBHFfMlqImBTFVBbgUtpZMG8kMWEFNCUZKrfPciFKyqgYm4QRdb3s33n2MNgyqa4KxbdzTujGoPJYRCTiCV__AtRt9XD4oCpSzAghEiG4h410I3tZq45tO-09FsPo2rX5Mq2hacRVNx9DlrnksO1v9RXZqI3C-BXSnf3-hELmQ8AUaAYMW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232549313</pqid></control><display><type>article</type><title>Major Hepatic Resection for Hilar Cholangiocarcinoma: Analysis of 46 Patients</title><source>MEDLINE</source><source>American Medical Association Journals</source><source>Alma/SFX Local Collection</source><creator>Rea, David J ; Munoz-Juarez, Manuel ; Farnell, Michael B ; Donohue, John H ; Que, Florencia G ; Crownhart, Brian ; Larson, Dirk ; Nagorney, David M</creator><creatorcontrib>Rea, David J ; Munoz-Juarez, Manuel ; Farnell, Michael B ; Donohue, John H ; Que, Florencia G ; Crownhart, Brian ; Larson, Dirk ; Nagorney, David M</creatorcontrib><description>HYPOTHESIS Major hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma are associated with actual long-term (&gt;5 years) survival. DESIGN Retrospective outcome study. SETTING Single tertiary referral institution. PATIENTS Between 1979 and 1997, 46 consecutive patients had resection of hilar cholangiocarcinoma by major hepatectomy, bile duct resection, and regional lymphadenectomy. MAIN OUTCOME MEASURES Overall survival and tumor recurrence were correlated to clinicopathological factors, operative morbidity, and mortality. RESULTS Twenty-five patients underwent left hepatectomy, 17 underwent right hepatectomy, and 4 had extended right hepatectomy. Eighteen patients underwent resection of segment 1. Negative (R0) resection margins were achieved in 37 patients (80%). The operative mortality rate was 9%, and the surgical morbidity rate was 52%. Actual 1-year, 3-year, and 5-year survival rates were 80%, 39%, and 26%, respectively. Factors adversely associated with patient survival rates included: male sex, lymph node metastases, tumor grade 3 or 4, elevated direct serum bilirubin level at diagnosis, elevated preoperative activated partial thromboplastin time, and more than 4 U of red blood cells transfused perioperatively. Tumor size and R0 resection approached significance for survival. Factors associated with tumor recurrence included: male sex, tumor grade 3 or 4, a low hemoglobin level both at diagnosis and preoperatively, and a low preoperative prothrombin time and low alkaline phosphatase level at diagnosis and preoperatively. Median time to recurrence was 3.6 years. Tumor recurrence was predominantly local and regional. CONCLUSIONS The actual 5-year survival rate of 26% justifies major partial hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma. The high frequency of local and regional recurrence warrants investigation of adjuvant therapy.Arch Surg. 2004;139:514-525--&gt;</description><identifier>ISSN: 0004-0010</identifier><identifier>ISSN: 2168-6254</identifier><identifier>EISSN: 1538-3644</identifier><identifier>EISSN: 2168-6262</identifier><identifier>DOI: 10.1001/archsurg.139.5.514</identifier><identifier>PMID: 15136352</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Aged ; Bile Duct Neoplasms - mortality ; Bile Duct Neoplasms - pathology ; Bile Duct Neoplasms - surgery ; Bile Ducts, Intrahepatic - surgery ; Cholangiocarcinoma - mortality ; Cholangiocarcinoma - pathology ; Cholangiocarcinoma - surgery ; Female ; Hepatectomy ; Humans ; Lymph Node Excision ; Male ; Middle Aged ; Neoplasm Invasiveness ; Proportional Hazards Models ; Retrospective Studies ; Survival Analysis</subject><ispartof>Archives of surgery (Chicago. 1960), 2004-05, Vol.139 (5), p.514-525</ispartof><rights>Copyright American Medical Association May 2004</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamasurgery/articlepdf/10.1001/archsurg.139.5.514$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/archsurg.139.5.514$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,315,781,785,3341,27926,27927,76491,76494</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15136352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rea, David J</creatorcontrib><creatorcontrib>Munoz-Juarez, Manuel</creatorcontrib><creatorcontrib>Farnell, Michael B</creatorcontrib><creatorcontrib>Donohue, John H</creatorcontrib><creatorcontrib>Que, Florencia G</creatorcontrib><creatorcontrib>Crownhart, Brian</creatorcontrib><creatorcontrib>Larson, Dirk</creatorcontrib><creatorcontrib>Nagorney, David M</creatorcontrib><title>Major Hepatic Resection for Hilar Cholangiocarcinoma: Analysis of 46 Patients</title><title>Archives of surgery (Chicago. 1960)</title><addtitle>Arch Surg</addtitle><description>HYPOTHESIS Major hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma are associated with actual long-term (&gt;5 years) survival. DESIGN Retrospective outcome study. SETTING Single tertiary referral institution. PATIENTS Between 1979 and 1997, 46 consecutive patients had resection of hilar cholangiocarcinoma by major hepatectomy, bile duct resection, and regional lymphadenectomy. MAIN OUTCOME MEASURES Overall survival and tumor recurrence were correlated to clinicopathological factors, operative morbidity, and mortality. RESULTS Twenty-five patients underwent left hepatectomy, 17 underwent right hepatectomy, and 4 had extended right hepatectomy. Eighteen patients underwent resection of segment 1. Negative (R0) resection margins were achieved in 37 patients (80%). The operative mortality rate was 9%, and the surgical morbidity rate was 52%. Actual 1-year, 3-year, and 5-year survival rates were 80%, 39%, and 26%, respectively. Factors adversely associated with patient survival rates included: male sex, lymph node metastases, tumor grade 3 or 4, elevated direct serum bilirubin level at diagnosis, elevated preoperative activated partial thromboplastin time, and more than 4 U of red blood cells transfused perioperatively. Tumor size and R0 resection approached significance for survival. Factors associated with tumor recurrence included: male sex, tumor grade 3 or 4, a low hemoglobin level both at diagnosis and preoperatively, and a low preoperative prothrombin time and low alkaline phosphatase level at diagnosis and preoperatively. Median time to recurrence was 3.6 years. Tumor recurrence was predominantly local and regional. CONCLUSIONS The actual 5-year survival rate of 26% justifies major partial hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma. The high frequency of local and regional recurrence warrants investigation of adjuvant therapy.Arch Surg. 2004;139:514-525--&gt;</description><subject>Aged</subject><subject>Bile Duct Neoplasms - mortality</subject><subject>Bile Duct Neoplasms - pathology</subject><subject>Bile Duct Neoplasms - surgery</subject><subject>Bile Ducts, Intrahepatic - surgery</subject><subject>Cholangiocarcinoma - mortality</subject><subject>Cholangiocarcinoma - pathology</subject><subject>Cholangiocarcinoma - surgery</subject><subject>Female</subject><subject>Hepatectomy</subject><subject>Humans</subject><subject>Lymph Node Excision</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><issn>0004-0010</issn><issn>2168-6254</issn><issn>1538-3644</issn><issn>2168-6262</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1PxCAURYnR6PjxA3RhGhfuWoEHlLqbTPxKZqIxuiaU0plO2jJCu_Dfi5lRE1cQOPe-l4PQBcEZwZjcaG9WYfTLjECR8YwTtocmhINMQTC2jyYYY5ZGEh-h4xDW8UZlQQ_REeEEBHA6QYuFXjufPNqNHhqTvNpgzdC4Pqm_X5tW-2S2cq3ul40zcWDTu07fJtNet5-hCYmrEyaSlxi2_RBO0UGt22DPducJer-_e5s9pvPnh6fZdJ5qWvAhrSRQzIoqrxnBHFfMlqImBTFVBbgUtpZMG8kMWEFNCUZKrfPciFKyqgYm4QRdb3s33n2MNgyqa4KxbdzTujGoPJYRCTiCV__AtRt9XD4oCpSzAghEiG4h410I3tZq45tO-09FsPo2rX5Mq2hacRVNx9DlrnksO1v9RXZqI3C-BXSnf3-hELmQ8AUaAYMW</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Rea, David J</creator><creator>Munoz-Juarez, Manuel</creator><creator>Farnell, Michael B</creator><creator>Donohue, John H</creator><creator>Que, Florencia G</creator><creator>Crownhart, Brian</creator><creator>Larson, Dirk</creator><creator>Nagorney, David M</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20040501</creationdate><title>Major Hepatic Resection for Hilar Cholangiocarcinoma: Analysis of 46 Patients</title><author>Rea, David J ; Munoz-Juarez, Manuel ; Farnell, Michael B ; Donohue, John H ; Que, Florencia G ; Crownhart, Brian ; Larson, Dirk ; Nagorney, David M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a295t-d832049d7f41050d4eb6f191cdd30b6ef84ac84c3e62cb3c88aa77c6b84df3483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Bile Duct Neoplasms - mortality</topic><topic>Bile Duct Neoplasms - pathology</topic><topic>Bile Duct Neoplasms - surgery</topic><topic>Bile Ducts, Intrahepatic - surgery</topic><topic>Cholangiocarcinoma - mortality</topic><topic>Cholangiocarcinoma - pathology</topic><topic>Cholangiocarcinoma - surgery</topic><topic>Female</topic><topic>Hepatectomy</topic><topic>Humans</topic><topic>Lymph Node Excision</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><toplevel>online_resources</toplevel><creatorcontrib>Rea, David J</creatorcontrib><creatorcontrib>Munoz-Juarez, Manuel</creatorcontrib><creatorcontrib>Farnell, Michael B</creatorcontrib><creatorcontrib>Donohue, John H</creatorcontrib><creatorcontrib>Que, Florencia G</creatorcontrib><creatorcontrib>Crownhart, Brian</creatorcontrib><creatorcontrib>Larson, Dirk</creatorcontrib><creatorcontrib>Nagorney, David M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of surgery (Chicago. 1960)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rea, David J</au><au>Munoz-Juarez, Manuel</au><au>Farnell, Michael B</au><au>Donohue, John H</au><au>Que, Florencia G</au><au>Crownhart, Brian</au><au>Larson, Dirk</au><au>Nagorney, David M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Major Hepatic Resection for Hilar Cholangiocarcinoma: Analysis of 46 Patients</atitle><jtitle>Archives of surgery (Chicago. 1960)</jtitle><addtitle>Arch Surg</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>139</volume><issue>5</issue><spage>514</spage><epage>525</epage><pages>514-525</pages><issn>0004-0010</issn><issn>2168-6254</issn><eissn>1538-3644</eissn><eissn>2168-6262</eissn><abstract>HYPOTHESIS Major hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma are associated with actual long-term (&gt;5 years) survival. DESIGN Retrospective outcome study. SETTING Single tertiary referral institution. PATIENTS Between 1979 and 1997, 46 consecutive patients had resection of hilar cholangiocarcinoma by major hepatectomy, bile duct resection, and regional lymphadenectomy. MAIN OUTCOME MEASURES Overall survival and tumor recurrence were correlated to clinicopathological factors, operative morbidity, and mortality. RESULTS Twenty-five patients underwent left hepatectomy, 17 underwent right hepatectomy, and 4 had extended right hepatectomy. Eighteen patients underwent resection of segment 1. Negative (R0) resection margins were achieved in 37 patients (80%). The operative mortality rate was 9%, and the surgical morbidity rate was 52%. Actual 1-year, 3-year, and 5-year survival rates were 80%, 39%, and 26%, respectively. Factors adversely associated with patient survival rates included: male sex, lymph node metastases, tumor grade 3 or 4, elevated direct serum bilirubin level at diagnosis, elevated preoperative activated partial thromboplastin time, and more than 4 U of red blood cells transfused perioperatively. Tumor size and R0 resection approached significance for survival. Factors associated with tumor recurrence included: male sex, tumor grade 3 or 4, a low hemoglobin level both at diagnosis and preoperatively, and a low preoperative prothrombin time and low alkaline phosphatase level at diagnosis and preoperatively. Median time to recurrence was 3.6 years. Tumor recurrence was predominantly local and regional. CONCLUSIONS The actual 5-year survival rate of 26% justifies major partial hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma. The high frequency of local and regional recurrence warrants investigation of adjuvant therapy.Arch Surg. 2004;139:514-525--&gt;</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>15136352</pmid><doi>10.1001/archsurg.139.5.514</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0004-0010
ispartof Archives of surgery (Chicago. 1960), 2004-05, Vol.139 (5), p.514-525
issn 0004-0010
2168-6254
1538-3644
2168-6262
language eng
recordid cdi_proquest_miscellaneous_71911830
source MEDLINE; American Medical Association Journals; Alma/SFX Local Collection
subjects Aged
Bile Duct Neoplasms - mortality
Bile Duct Neoplasms - pathology
Bile Duct Neoplasms - surgery
Bile Ducts, Intrahepatic - surgery
Cholangiocarcinoma - mortality
Cholangiocarcinoma - pathology
Cholangiocarcinoma - surgery
Female
Hepatectomy
Humans
Lymph Node Excision
Male
Middle Aged
Neoplasm Invasiveness
Proportional Hazards Models
Retrospective Studies
Survival Analysis
title Major Hepatic Resection for Hilar Cholangiocarcinoma: Analysis of 46 Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T11%3A40%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Major%20Hepatic%20Resection%20for%20Hilar%20Cholangiocarcinoma:%20Analysis%20of%2046%20Patients&rft.jtitle=Archives%20of%20surgery%20(Chicago.%201960)&rft.au=Rea,%20David%20J&rft.date=2004-05-01&rft.volume=139&rft.issue=5&rft.spage=514&rft.epage=525&rft.pages=514-525&rft.issn=0004-0010&rft.eissn=1538-3644&rft_id=info:doi/10.1001/archsurg.139.5.514&rft_dat=%3Cproquest_cross%3E638023181%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232549313&rft_id=info:pmid/15136352&rft_ama_id=396768&rfr_iscdi=true